Literature DB >> 16476871

Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department.

James L Januzzi1, Rahul Sakhuja, Michelle O'donoghue, Aaron L Baggish, Saif Anwaruddin, Claudia U Chae, Renee Cameron, Daniel G Krauser, Roderick Tung, Carlos A Camargo, Donald M Lloyd-Jones.   

Abstract

BACKGROUND: Amino-terminal pro-brain natriuretic peptide (NT-proBNP) is useful for diagnosis and triage of patients with dyspnea, but its role for predicting outcomes in such patients remains undefined.
METHODS: A total of 599 breathless patients treated in the emergency department were prospectively enrolled, and a sample of blood was obtained for NT-proBNP measurements. After 1 year, the vital status of each patient was ascertained, and the association between NT-proBNP values at presentation and mortality was assessed.
RESULTS: At 1 year, 91 patients (15.2%) had died. Median NT-proBNP concentrations at presentation among decedents were significantly higher than those of survivors (3277 vs 299 pg/mL; P<.001). The optimal NT-proBNP cut point for predicting 1-year mortality was 986 pg/mL. In a multivariable model, an NT-proBNP concentration greater than 986 pg/mL at presentation was the single strongest predictor of death at 1 year (hazard ratio [HR], 2.88; 95% confidence interval, 1.64-5.06; P<.001), independent of a diagnosis of heart failure. Other factors associated with death included age (by decade; HR, 1.20), heart rate (by decile; HR, 1.13), urea nitrogen level (by decile; HR, 1.20), systolic blood pressure less than 100 mm Hg (HR, 1.94), heart murmur (HR, 1.92), and New York Heart Association classification (HR, 1.38 for each increase in class). The NT-proBNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0.76 for predicting mortality; the other significant covariates combined had an AUC of 0.80. The final model for predicting death, combining NT-proBNP with other covariates associated with mortality, had a superior AUC of 0.82.
CONCLUSION: In addition to assisting in emergency department diagnosis and triage, NT-proBNP concentrations at presentation are strongly predictive of 1-year mortality in dyspneic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476871     DOI: 10.1001/archinte.166.3.315

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  47 in total

1.  Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.

Authors:  Ravi V Shah; Quynh A Truong; Hanna K Gaggin; Jens Pfannkuche; Oliver Hartmann; James L Januzzi
Journal:  Eur Heart J       Date:  2012-05-29       Impact factor: 29.983

Review 2.  Biomarker guided therapy for heart failure: focus on natriuretic peptides.

Authors:  Kirkwood F Adams; G Michael Felker; Ghassan Fraij; J Herbert Patterson; Christopher M O'Connor
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 3.  Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.

Authors:  Catherine N Marti; Gregg C Fonarow; Stefan D Anker; Clyde Yancy; Muthiah Vaduganathan; Stephen J Greene; Ali Ahmed; James L Januzzi; Mihai Gheorghiade; Gerasimos Filippatos; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-12-10       Impact factor: 15.534

Review 4.  Remote Monitoring to Reduce Heart Failure Readmissions.

Authors:  Sitaramesh Emani
Journal:  Curr Heart Fail Rep       Date:  2017-02

Review 5.  Biomarkers in heart failure: the past, current and future.

Authors:  Michael Sarhene; Yili Wang; Jing Wei; Yuting Huang; Min Li; Lan Li; Enoch Acheampong; Zhou Zhengcan; Qin Xiaoyan; Xu Yunsheng; Mao Jingyuan; Gao Xiumei; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 6.  Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2.

Authors:  Antonio J Vallejo-Vaz
Journal:  Eur Cardiol       Date:  2015-07

7.  N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy.

Authors:  Gerald Chi; James L Januzzi; Serge Korjian; Yazan Daaboul; Samuel Z Goldhaber; Adrian F Hernandez; Russell D Hull; Alex Gold; Alexander T Cohen; Robert A Harrington; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

8.  [Essential cardiac biomarkers in myocardial infarction and heart failure].

Authors:  M Mueller; E Giannitsis; H A Katus
Journal:  Herz       Date:  2014-09       Impact factor: 1.443

9.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials.

Authors:  Jonathan G Howlett; Robert S McKelvie; J Malcolm O Arnold; Jeannine Costigan; Paul Dorian; Anique Ducharme; Estrellita Estrella-Holder; Justin A Ezekowitz; Nadia Giannetti; Haissam Haddad; George A Heckman; Anthony M Herd; Debra Isaac; Philip Jong; Simon Kouz; Peter Liu; Elizabeth Mann; Gordon W Moe; Ross T Tsuyuki; Heather J Ross; Michel White
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

10.  The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.

Authors:  Van Kimmenade
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.